Improving Management Strategies and Patient
Adherence in the Treatment of Psoriasis

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 25, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by an educational grant from
Novartis Pharmaceuticals

Description:
Psoriasis is a complex, chronic, immune-mediated inflammatory disease that affects approximately 7 million, or just over 2%, of the population in the United States. The disease most commonly appears on the skin of the scalp, elbow, knees, and lumboscaral areas of the body. Psoriasis is a complex disease to manage with a greatly undeserved patient population, and the goal should be a patient-centered treatment that reduces disease burden, improves on quality-of-life, and addresses the risks of systemic complications and comorbid conditions. Early diagnosis and treatment may help to reduce the economic burden. Physicians usually classify the disease as mild to severe which can help determine the best treatment strategies for the patient.

Treatment options are based on the severity of the disease and may include topical treatments, phototherapy, and laser therapy. However, should these therapies prove unsuccessful, especially in moderate to severe psoriasis, other treatments may be utilized. These treatments include traditional systemic medication, which may be prescribed orally or by injection, newer oral medications which are targeted small molecule medications, and biologics. Biologics require a reliable baseline of laboratory tests, regular blood testing, and patient education regarding the effect of biologics on their immune system and what vaccines they can have or must avoid. Biologics can be very effective in the treatment of psoriasis, but proper management must be done in order to assure the best safety and efficacy for the patient. Although biologic therapies are becoming more available and represent a significant safety advance over traditional systemic therapies, most of the patients receiving current systemic agents are not being treated with biologics.

Upon Completion of this activity, participants will be able to:

  • Analyze the latest clinical data pertaining to current and emerging therapeutic options, including biologics, for psoriasis

  • Identify guideline recommendations for early screening, diagnosis, and treatment selections for patients with psoriasis

  • Discuss emerging therapeutic options that can achieve new treatment targets in patients who do not respond to traditional therapies

  • Explore the pathogenesis associated with the development and progression of psoriasis, and how this relates to current and emerging biologic therapies

  • Explore the burden of psoriasis and the impact that undertreatment and nonadherence has on comorbidities, quality of life and work productivity
     

Faculty: Steven R. Feldman, MD, PhD
Professor of Dermatology
Department of Dermatology
Wake Forest University School of Medicine

Disclosure:

Dr. Feldman serves as a consultant and/or speaker to AbbVie Inc., Advance, Caremark, Celgene, Galderma, Gerson Lehrman Group, Guidepoint Global, Janssen, Leo Pharma Inc., Leo Pharma Inc., Lilly, Merck & Co., Inc., Mylan, Novartis Pharmaceuticals Corporation, Pfizer Inc., Qurient, Sanofi, Suncare, Taro and Xenoport. Dr. Feldman receives research/grant support from AbbVie Inc., Celgene, Janssen, Novartis Pharmaceuticals Corporation, Taro, Galderma, Pfizer Inc., Qurient, and Sanofi. Dr. Feldman receives royalties from Informa, UpToDate, Xlibris and owns stock in Causa Technologies and Medical Quality Enhancement. His presentation has been peer reviewed.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Jacquelyn Smith has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation

The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by an educational grant from
Novartis Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue